HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Medi-Physics/Amersham Healthcare

Executive Summary

Medi-Physics/Amersham Healthcare: U.S. arm of U.K. parent Amersham signs Adenoscan distribution agreement with Fujisawa USA, which licenses the adenosine injection from Medco Research. Adenoscan was approved May 18 for evaluating cardiac function in patients who cannot undergo a stress test ("The Pink Sheet" May 22, T&G-3). The agreement with Fujisawa will allow Medi-Physics to distribute Adenoscan through its Pharmacy Network of "more than 115 radiopharmacies to their customers," Arlington Heights, Ill.-based Medi-Physics reports. Medi-Physics said July 17 it received an "approvable" letter from FDA for its cardiac perfusion agent Myoview (kit for the preparation of technetium Tc-99m tetrofosmin)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026673

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel